Invasive Aspergillosis

• FDA approval · 2015-02-03
  FDA Approved: VFEND — Supplemental Application (Roerig)

  FDA approved a supplemental application for VFEND (voriconazole) from Roerig, resulting in an update/expansion of the product's labeling.

• FDA approval · 2014-04-07
  FDA Approved: VFEND — Supplemental Application (Roerig)

  FDA approved a supplemental application for VFEND (voriconazole) submitted by Roerig.

• FDA approval · 2013-12-18
  FDA Approved: CANCIDAS — Supplemental Application (Merck Sharp & Dohme LLC)

  FDA approved a supplemental application for CANCIDAS (caspofungin acetate) from Merck Sharp & Dohme LLC to update its labeling.

• FDA approval · 2013-11-25
  FDA Approved: NOXAFIL — Original Application (Merck Sharp & Dohme LLC)

  FDA approves NOXAFIL (posaconazole) through Merck's original NDA. The approval recognizes posaconazole for prevention and treatment of invas…

• FDA approval · 2012-05-30
  FDA Approved: VORICONAZOLE — Original Application (Sandoz Inc)

  The FDA approved Sandoz Inc's original application for a generic Voriconazole, enabling its marketing in the United States for the same indi…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2011-06-01
  FDA Approved: VFEND — Supplemental Application (Roerig)

  FDA approved a supplemental application for VFEND (voriconazole) submitted by Roerig. The page provides no details on the specific change.

• FDA approval · 2010-11-21
  FDA Approved: VFEND — Supplemental Application (Roerig)

  FDA approved a supplemental application for VFEND (voriconazole) submitted by Roerig. The supplement updates the labeling for the antifungal…

• FDA approval · 2008-03-10
  FDA Approved: VFEND — Supplemental Application (Roerig)

  FDA approved a supplemental application for VFEND (voriconazole) filed by Roerig.